Navigation Links
Aurigene Highlights its PD-1 peptide, Bet Bromodomain and NAMPT Inhibitors Program at AACR 2013
Date:4/2/2013

BANGALORE, India and BRIDGEWATER, New Jersey, April 2, 2013 /PRNewswire/ --

Aurigene will be presenting poster sessions for three of its programs at the American Associate of Cancer Research (April 6-10 in Washington, DC).

     (Logo: http://photos.prnewswire.com/prnh/20130402/606920)

PD-1 is a 29-amino acid novel peptide (NP-12) that displays sub-nM potency in disruption of PD1-PDL1/L2 interactions. NP-12 is highly effective in antagonizing PD1 signalling, with desirable in vivo exposure upon s.c. dosing. NP-12 inhibits tumor growth and metastasis in preclinical models of cancer and is well tolerated with no overt toxicity at any of the tested doses; currently in IND studies.

Session Title: Equipotent antagonism, transient immune activation and excellent antitumor efficacy with a peptide inhibitor of PD-1 immune check point pathway

ID: Cytokines, Modification of the Tumor Microenvironment, and Intervention - 1231/11 PO.IM02.02.

Date and Time: Mon, Apr 8, 1:00 - 5:00 PM

Bet Bromodomain: Aurigene has identified novel chemical series of lead compounds that show excellent cell based activity. Demonstration of efficacy is on-going.

Session Title: Identification of potent BET bromodomain inhibitors for treatment of cancer

ID: Epigenetic Therapy and Risk Biomarkers 671/1 - PO.MCB06.05.

Date and Time: Sun, Apr 7, 1:00 - 5:00 PM

NAMPT: Aurigene has identified novel chemical series of compounds - lead compounds show excellent cell based activity correlating with biochemical potency, favorable ADME profile, excellent pharmacokinetic profile in mice with good oral bioavailability. The lead compound shows excellent efficacy with tumor regression in pancreatic cancer xenograft mice models. Preclinical studies on-going.

Session Title: Novel inhibitors of nicotinamide phosphoribosyl transferase (NAMPT)

ID: Molecular and Cellular Biology 72

Date and Time: Wednesday Apr 10, 2013 8:00 AM - 12:00 PM

Location: Hall A-C, Poster Section 33

Revised Permanent Abstract Number: 5389

About Aurigene

Aurigene is an India based biotech focussed on small molecule and peptide therapeutics for oncology, inflammation and anti-infectives. Our current pipeline includes several best-in-class and first-in-class assets for oncology and inflammation in preclinical/ IND stage. The most advanced programs include (a) PD-1 peptide therapy for oncology and antibacterial infections; (b) Matriptase - a novel protease for OA currently in preclinical studies; (c) FabI inhibitor in IND studies for MRSA. In addition, Aurigene is building a robust pipeline of early stage assets in emerging areas of cancer metabolism, epigenetics and the TH17 pathway. For more information, please visit the company's website at http://www.aurigene.com.

Media Contact:
Rajshree KT
Head Strategic Alliances
+91-40-4465-7777


'/>"/>
SOURCE Aurigene
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. The Foremost Expert on Morgellons Disease Highlights the Gravity of This Illness
2. Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts
3. Sequenom Announces 2011 Operational Highlights and Early 2012 Outlook
4. Soligenix Reports Year-End 2011 Financial Results and Highlights Recent Accomplishments
5. CMC Biologics Highlights Technical Acumen at Upcoming Conferences
6. Journal of Renewable and Sustainable Energy highlights energy trends in China
7. Enterologics Highlights Growing News on Probiotics on the Web
8. Recently Published Economic Analysis Highlights the Financial Impact of Attention-Deficit/Hyperactivity Disorder (ADHD) in the United States (US)
9. InterMune Reports Third Quarter 2012 Financial Results And Business Highlights
10. Advanced manufacturing venture highlights regions economic prospects
11. Amgen Highlights Data To Be Presented At American Society of Hematology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Calif. , June 23, 2016  The Prostate Cancer Foundation ... increasingly precise treatments and faster cures for prostate cancer. Members of the Class ... across 15 countries. Read More About the Class of ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report ... detail how a patient who developed lymphedema after being treated for breast cancer benefitted ... change the paradigm for dealing with this debilitating, frequent side effect of cancer treatment. ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only free ... and will showcase its product’s latest features from June 26 to June 30, ... poster on Disrupting Clinical Trials in The Cloud during the conference. DIA ...
(Date:6/22/2016)... SAN DIEGO , June 22, 2016 /PRNewswire/ ... partnership that will allow them to produce up ... (HiPSC) from one lot within one week. These ... their time laboriously preparing cells and spend more ... made possible through a proprietary, high-volume manufacturing process ...
Breaking Biology Technology:
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com , ... published the overview results from the Q1 wave of ... recent wave was consumers, receptivity to a program where ... with a health insurance company. "We were ... share," says Michael LaColla , CEO of Troubadour ...
(Date:4/28/2016)... and BANGALORE, India , April 28, ... Systems, a product subsidiary of Infosys (NYSE: INFY ... announced a global partnership that will provide end ... use mobile banking and payment services.      (Logo: ... key innovation area for financial services, but it also plays ...
(Date:4/26/2016)... , April 27, 2016 ... "Global Multi-modal Biometrics Market 2016-2020"  report to their ... , The analysts forecast the global ... of 15.49% during the period 2016-2020.  ... of sectors such as the healthcare, BFSI, transportation, ...
Breaking Biology News(10 mins):